Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PROPIVERINE HYDROCHLORIDE

All products: Limited Use (codes 530)

Mictoryl Pediatric · DIN 02460289 · 5mg · tablet

Limited Use — Reason for Use code 530 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 530 required
Write on scriptLU code 530 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 530
Reason for Use code 530 For the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients with overactive bladder. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Mictoryl Pediatric · DIN 02460289 Manufacturer: Duchesnay Inc.; listing date 2018-05-31 Health Canada: Marketed since 2017-04-13 · brand MICTORYL PEDIATRIC · ATC G04BD06 PROPIVERINE · form Tablet · route Oral · ingredients PROPIVERINE HYDROCHLORIDE 5 MG · company Duchesnay inc · schedule Prescription
Check this DIN again · Health Canada product record

Mictoryl Pediatric: Formulary list price $0.3889/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3889 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94757 · Verify on the e-Formulary ↗ (DIN 02460289)

Source record
DIN 02460289: Mictoryl Pediatric Raw flags: sec12=Y, sec3=Y Item: 861204001; group id 879; item number 2120; lccId 00303; manufacturer id DUI Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3889; ministry $0.3889 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02460289 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94757
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (86:12:04 Antimuscarinics) and how they are covered
No products matched this class search: “86:12:04”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: overactive bladder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DARIFENACIN · Limited Use, codes 290 INDICATIONS AND CLINICAL USE ENABLEX (darifenacin) is indicated for the treatment of overactive bladder. PM: https://pdf.hres.ca/dpd_pm/00049667.PDF; date not captured; DIN 02273217; fetched 2026-09-10 Product monograph MIRABEGRON · Limited Use, codes 290 INDICATIONS AND CLINICAL USE MYRBETRIQ (mirabegron) is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. PM: https://pdf.hres.ca/dpd_pm/00035298.PDF; date June 02, 2016; DIN 02402874; fetched 2026-09-10 Product monograph SOLIFENACIN SUCCINATE · Limited Use, codes 290 INDICATIONS AND CLINICAL USE VESICARE® (solifenacin succinate) is indicated for:  Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency. PM: https://pdf.hres.ca/dpd_pm/00048963.PDF; date December 31, 2018; DIN 02277263; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Mictoryl/Mictoryl Pediatric (propiverine hydrochloride) is indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB). Adults: Mictoryl 30 mg and 45 mg is indicated in adults including the geriatric population (>65 years of age). Pediatric population: Mictoryl Pediatric 5 mg is indicated for a body weight adjusted dosing in children from the age of 5 years with OAB up to a body weight of 35 kg. In children and adolescents with a body weight over 35 kg, the maximum recommended dose is 30 mg administered in two daily doses. There is only limited efficacy and safety data on children and adolescents of higher body weight (≥35 kg) receiving daily dose of 30 mg propiverine. Mictoryl®/Mictoryl® Pediatric Product Monograph Page 3 of 39 https://pdf.hres.ca/dpd_pm/00043480.PDF PM date: January 15, 2018 Source product: MICTORYL PEDIATRIC; DIN 02460289; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.